Active, not recruitingPhase 1NCT04220944

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Studying Carcinoma of liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Zhongshan Hospital
Principal Investigator
zhiping Yan, MD
Department of Interventional Radiology, Zhongshan Hospital, Fudan University
Intervention
Sintilimab(drug)
Enrollment
45 enrolled
Eligibility
18-80 years · All sexes
Timeline
20202024

Study locations (1)

Collaborators

Innovent Biologics (Suzhou) Co. Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04220944 on ClinicalTrials.gov

Other trials for Carcinoma of liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of liver and intrahepatic biliary tract

← Back to all trials